Reading Time: 5 minutesThere is a desperate need for a biomarker for MND for both the diagnosis and demonstration of a biological effect as a result of a
Tag: Martin Turner
Reading Time: 4 minutesAfter its successful premiere in 2017, the University of Oxford organised another meeting of people affected by inherited MND, called ‘Families for the Treatment of
Reading Time: 10 minutes“The annals of ALS clinical trials is strewn with failed studies. Only two out of more than 70 clinical trials have been positive, and even
Reading Time: 3 minutesIt has been almost a year since we announced that AMBRoSIA (A Multicentre Biomarker Resource Strategy In ALS) had begun to recruit participants (read the
Reading Time: 4 minutesThis article was written by our Senior Clinical Fellow Prof Martin Turner, a Consultant Neurologist at John Radcliffe Hospital, Oxford. “Will it affect my children?”
Reading Time: 4 minutesConferences and symposia are a crucial part of the research world – not only for the amount of knowledge that is communicated to large audiences
Reading Time: 4 minutesIn April this year MND clinician-researchers Professors Martin Turner and Kevin Talbot at the University of Oxford organised an information day about the rare, inherited
Reading Time: 3 minutesThe AMBRoSIA (A Multicentre Biomarker Resource Strategy In ALS) project is our biggest, most ambitious research undertaking to date. The project funding began in August,
Reading Time: 2 minutesBiomarkers in Oxford (BioMOx) is a research project with the aim of identifying a diagnostic biomarker for MND, which could be used to track the
Reading Time: 3 minutesThe fantastic news that Patrick Joyce and his co-inventors have won the 2015 Hackaday Prize for their ‘Eyedrivomatic’ invention is one of a number of research